More Than Half Of COVID-19 Patients In New Study Have Heart Damage
13/7/20: COVID19 Update: Russia
Pfizer, BioNTech Score Fast Track Status For Covid-19 Vaccine Candidates
South Korea: 1 in 3 Covid-19 Patients Improved With Gilead’s Remdesivir
Amgen Pours A Further $421M Into China’s BeiGene
BeiGene Plans $2B Direct Offering; Analyst Sees Further Upside Ahead
ElectroCore Pops 160% On FDA Nod For Covid-19 Asthma Device
Racial disparities in COVID-19 are clear; better data, more targeted action needed
Mothers, newborns, young children and adolescents lose 20% of health and social services to COVID-19
What Economists Can Teach Epidemiologists
Australia Provisionally Approves Gilead’s Covid-19 Treatment
Xeris Pharma Spikes 12% After-Hours On Soros Stake; Analyst Says Buy
Gilead Reveals Additional Data On Covid-19 Treatment Remdesivir
Official COVID-19 Statistics Are Missing Something Critical
Florida Suffers Record Single-Day Jump In COVID-19 Deaths: Live Updates
Remdesivir Shows Broader Effectiveness Against Covid-19
EU Close: Modest de-risking ahead of Earnings Season and on US virus concerns, Oil rises, Gold holds $1800 level
Goldman Spots An Ominous Turning Point In The US Coronavirus Pandemic
World Suffers 3rd Straight Record Jump In New COVID-19 Cases As US Sees Disturbing Spike In Deaths: Live Updates
About half of health care workers positive for COVID-19 by serology have no symptoms
Preliminary study suggests tuberculosis vaccine may be limiting COVID-19 deaths
5 COVID-19 myths politicians have repeated that just aren't true
Data mining system unearths US counties most at risk for COVID deaths
Trump and Navarro press again for hydroxychloroquine. Can the FDA stay independent?
UK trial begins testing second-wave COVID-19 drug from US biotech Ridgeback
3 ways to improve COVID-19 response to elderly care and persons with disabilities
JPMorgan Turns Bearish, Sees "Unattractive Risk-Reward" For Stocks In H2
3 Coronavirus Penny Stocks With Triple-Digit Upside Potential
3 Penny Stocks to Benefit From the Coronavirus Outbreak
J.P. Morgan: These 3 Stocks Are Poised to Surge by at Least 20%